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Abstract It is not highly sophisticated, yet the N→S acyl transfer reaction of a 
native peptide sequence potentially fills an important technology gap.  While 
several routes to synthetic peptide thioesters exist, only one is routinely 
applicable for biologically derived samples.  Using the naturally occurring 
amino acid cysteine as the sole activator for N→S acyl transfer we have 
demonstrated transformation of synthetic and biologically derived 
precursors into thioesters for use in Native Chemical Ligation, providing a 
viable alternative for biological samples.  Further refinement will be key to 
realizing the full potential of this intriguing process, and increase the number 
of applications in peptide engineering and therapeutics. 
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1  Introduction 
The thioester has attracted the interest of scientists for decades 
and due to its ubiquitous presence in cellular metabolism it is 
considered highly relevant to prebiotic chemistry and the 
origins of life.1 The peptide Cα-thioester (1) also sits centrally as 
a key tool for protein synthesis and semi-synthesis using Native 
Chemical Ligation (NCL, Scheme 1a).2   The early observations of 
Wieland (Scheme 1b),3 the advent of efficient automated solid 
phase-peptide assembly protocols,4 and the development of NCL 
by the Kent group have brought small proteins under the 
command of the synthetic organic chemist,5 and it is the ability 
to routinely engineer proteins at atomic level that has allowed 
their structure and function to be dissected in unprecedented 
detail.  As with NCL, the reverse process involving N→S acyl 
transfer (Scheme 1c) had been of interest, and subject to 
considerable study, over half a century ago.6   However it was 
not until much later, after the observation of N→S acyl transfer 
mediated by protein splicing elements called inteins,7 that the 
compatibility of this transformation with more complex protein 
components was explored in detail.  Pioneering research by 
Zanotti,8 Vorherr and Aimoto,9, 10 Melnyk (Scheme 1d, 1e, and 1f 
respectively),11 and others had shown that N→S acyl shift could 
be initiated to form thioesters under acidic or mildly basic 
conditions, highlighting the potential of this process for peptide 













Scheme 1  a) Mechanism of Native Chemical ligation (NCL) b) An NCL-like 
active ester condensation between a valine thioester and cysteine and c) The 
reverse process studied in the context of glutathione.  Both NCL and N→S 
acyl transfer were investigated in the 1950’s.3, 6 d)-f) Pioneering thioester 
syntheses, utilising N→S acyl transfer developed in subsequent years.8, 9, 11 p-
NP = para-nitrophenyl, TFA = trifluoroacetic acid, TIPS = triisopropylsilyl.
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 Further study of inteins demonstrated that the seemingly 
unfavourable N→S acyl shift was achieved through a 
combination of highly conserved catalytic residues and a 
distorted amide bond geometry,13, 14  and although the precise 
details of amide bond geometry in an active intein remain 
unclear,15 the notion that the scissile peptide bond requires 
distortion or weakening (ground state destabilization) through 
ancillary structural or stereoelectronic effects has served as the 
working model for the most recent synthetic developments. 
 In this short account we discuss our own unexpected 
exploration of N→S acyl transfer in native peptide sequences.  It 
was prompted by the observation of amide bond cleavage at 
Xaa-Cys motifs, with accompanying thioester formation, upon 
heating in aqueous mercaptopropionic acid (MPA). Rather than 
recounting the details of our findings to date we hope to 
highlight some key advantages of employing this simple 
methodology, and its relevance to NCL.  At the same time we 
emphasise some of the challenges that remain and suggest how 
they could be overcome in the near future. 
 Since its introduction,16 practitioners of NCL have sought to 
improve and simplify the process.  Initially this was based 
around finding efficient methods for the synthesis of the 
required thioester and cysteinyl components14, 17, 18, 19 but as the 
methodology developed the emphasis shifted towards 
performing multiple ligation reactions sequentially in one pot, 
and minimising handling steps.20  These streamlining processes 
typically comprise one pot kinetically controlled ligations, 21, 22 
combined with in-situ removal of protecting groups22, 23 and 
desulfurisation.24  The desire to conduct in-situ desulfurisation 
was prompted by the rapid growth, and effective use, of 
mercapto amino acid derivatives capable of performing NCL-
reactions,25 yet are reverted to non-cysteinyl amino acids upon 
reduction under mild conditions (Scheme 2a).26 This advance 
circumvents the often stated limitation that NCL requires 
cysteine, a relatively rare amino acid, at the ligation junction.  
The issue was also previously tackled through the use of 
removable acyl transfer auxiliaries (Scheme 2b)27 but these 
appendages were often criticized for their inability to perform 
NCL efficiently across ligation junctions other than Gly-Gly.  In 
our own laboratory we found auxiliaries to work effectively 
across several Xaa-Gly and Gly-Xaa junctions so long as typical 
NCL thiol additives were removed from the reaction.28  
Nevertheless this perceived difficulty, along with their poor 
atom economy and known potential to reverse amide bond 
formation (Scheme 1e),9, 29 has fuelled the search for 
alternatives even though recent developments that combine 
their relative ease of synthesis with improved performance 
across an increased variety of ligation junctions holds promise.30 
 Despite the growing number of options available to the 
synthetic chemist, NCL practitioners, who are often biologists, 
may seek a less sophisticated approach, one that does not 
require specific expertise or specialized apparatus.  Even 
chemists can become frustrated by the poor availability and 
high cost of amino acid analogues or acyl transfer auxiliaries.  
Furthermore their added substitution (relative to cysteine) 
means they don’t “perform” like cysteine in NCL reactions and 
their behaviours can be laced with idiosyncrasy, or necessitate 
the use of protecting groups to prevent off-target side-reactions.  
Meanwhile conservative point mutations are often well 
tolerated by proteins, and so the strategic substitution of non-
catalytic residues in order to facilitate NCL is also commonplace 
and consequently, introduction of additional “rogue” cysteine 
residues (which can perhaps be capped at a later stage) may still 
present the more attractive option.   Such corner-cutting often 
means that chemical yield or absolute replication of a natural 
structure are compromised in order to progress from A to 
something that closely resembles B in a timely and cost-effective 
manner, but the “cost” of such compromise ultimately depends 
on the experimental question being asked, and may be 
negligible.  If a favourable outcome is achieved then it is clear 
that, on balance, practical considerations far outweigh 
perfection.  Indeed, prior to the development of 4-
mercaptophenyl acetic acid (MPAA) as an NCL catalyst,31 many 
researchers would more routinely employ sodium 2-
mercaptoethanesulfonate (MESNa) as an NCL additive in place 
of the superior  thiophenol because of its low odour, high water 
solubility, reduced requirement for handling in an inert 
atmosphere, despite its relatively poor reaction kinetics.32  So, in 
the right setting, simplicity can trump sophistication and 
efficiency, setting the scene for our investigations concerning 
N→S acyl transfer. 
 
2  N→S acyl transfer in “normal” peptide sequences. 
While streamlined NCL protocols that minimise sample loss 
resulting from repeated purification steps are crucial, 
production of the required thioester component has remained 
the subject of continuous innovation and development too.  Our 
entry into this area began out of an interest in the compatibility, 
or lack thereof, between thioester synthesis and glycopeptides. 
 
Scheme 2  Common extensions of the NCL methodology, designed to abrogate the need for cysteine at the N-terminus of one peptide component
Synlett Account / Synpacts 
Template for SYNLETT © Thieme  Stuttgart · New York 2018-11-01 page 3 of 12 
The superior quality and efficiency of tert-butyloxycarbonyl 
(Boc)-based thioester synthesis had been well documented33 
but the harsh cleavage protocol (usually anhydrous HF) 
rendered Boc-based approaches incompatible with certain 
glycosides, and the high toxicity of HF combined with the 
requirement for specialist apparatus proved unattractive.  This 
obstacle has largely been overcome by the recent introduction 
of elegant non-HF based cleavage protocols34 but 9-
fluorenylmethoxycabonyl (Fmoc)-based glycopeptide 
syntheses currently remain the most common.35   While 
exceptions exist,36 Fmoc thioester syntheses are usually indirect 
since the thioester linkage itself is not compatible with 
piperidine mediated Fmoc cleavage,37 and the thioester is 
introduced upon cleavage from the solid support or post-
synthesis.  We initially experimented with the sulphonamide 
“safety-catch” approach which produced several long (>30 
residues) glycopeptide thioesters cleanly and reliably,38 but we 
also often grappled with the chemistry when thioester recovery 
was poor.  Although helpful methods for monitoring resin 
activation were emerging39 we craved an approach that was 
relatively easy to initiate, monitor and cleave, so turned towards 
post-synthesis N→S acyl transfer reactions.  The highest yielding 
peptide syntheses, in general, are those that furnish products as 
C- terminal carboxylates (e.g. using Wang resin) and 
carboxamides (e.g. using Rink amide resin) and post-synthesis 
thioester formation allowed precursors to be prepared in this 
way, so we attempted the method introduced by Zanotti 
(Scheme 1d) but optimised for peptide thioester synthesis by 
Aimoto and co-workers (Scheme 3).40 We reasoned that, even if 
thioester formation turned out to be problematic we would at 
least have ample material with which to optimise the process. 
Using the cysteinyl prolyl ester (CPE, 2) the unfavourable N→S 
acyl transfer is driven by sequestering the liberated α-amino 
group through rapid intramolecular diketopiperazine (DKP) 
formation in the presence of the proximal proline ester.   
Although peptide synthesis was conducted on Rink amide resin 
the resin-loading protocol is rather protracted.  The Xaa-Cys 
motif (where Xaa is potentially any amino acid residue) must be 
prepared separately and loaded as a dipeptide in order to 
prevent spontaneous DKP formation upon Fmoc deprotection 
from a resin bound Cys-Pro ester.  Nevertheless, precursor 
peptides were easily assembled and purified in good isolated 
yields.  However, upon exposure of a model peptide to typical 
reaction conditions (phosphate buffer; pH7, MESNa) little 
thioester was obtained unless an additional internal Cys residue 
was protected.  Enlightened by a further report of how an 
unreactive thioester precursor, similar to 2, could be salvaged 
employing 40% aqueous 3-mercaptopropionic acid (MPA) with 
microwave heating (60-80 oC),41 we subjected our model 
peptide to these conditions, resulting in cleavage of the peptide 
across an internal Gly-Cys motif (3) in addition to the terminal 
Cys-Pro-ester.42   
 Despite the literature precedent we were still surprised by 
this observation because productive thioester formation from 
native peptide sequences in this manner had not been described 
previously.  Furthermore, subjecting whole proteins (Bovine 
serum albumin and erythropoietin) to aqueous MPA at elevated 
temperature resulted in significant fragmentation across 
multiple Xaa-Cys sites with accompanying thioester formation.  
This observation was interesting because it hinted at potential 
application to biological samples even though native Xaa-Cys 
motifs were not considered sufficiently primed for 
fragmentation via N→S acyl transfer without the aid of an intein. 
 To explore the process further model reactions were 
conducted and monitored by HPLC and/or 13C NMR 
spectroscopy.10, 43  The commercial availability of 13C-1 labelled 
glycine allowed the effect of varying reaction conditions to be 
assessed rapidly using Gly-Cys terminated precursors and the 
overall picture that emerged was even more intriguing.  Not only 
did different Xaa-Cys motifs display varying aptitudes for 
thioester formation, but identical motifs (e.g Gly-Cys) were not 
equally reactive, depending on their sequence context (Figure 
1).44  In model studies several short peptide precursors 
containing particularly reactive C-terminal Xaa-Cys motifs 
(where Xaa = Gly, His or Cys) formed thioesters cleanly at 40-50 
oC over a period of 24-48 h.  In contrast, when the penultimate 
residue (Xaa) was a β-branched amino acid, thioester formation 
occurred slowly under forcing conditions (>60 oC), and was 
often accompanied by significant hydrolysis.  Moreover, when a 
favourable Xaa-Cys motif was placed within a peptide sequence, 
rather than at the terminus, the reaction rate was reduced 
further.  Surprisingly, even very small changes to the C-terminal 
Cys residue, when presented as a C-terminal ester or amide 
rather than carboxylate, caused the reaction rate to drop by 
approximately half under typical reaction conditions. The 
reason for the increased reactivity of the C-terminal Cys 
carboxylate may be due to the zwitterionic nature of the 
intermediate which increases the basicity of the liberated α- 
amino group and presents a barrier to reforming the starting 
material at acidic pH.45  Recently the enhanced reactivity of 







Scheme 3  Peptide Cα-thioester formation enabled by the cysteinyl prolyl ester (2)40 and by a single cysteine residue (3).42  
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Figure 1 “Some are more equal than others”. a) Following thioester formation 
using 13C-1 labelled glycine and 13C NMR spectroscopy.  b) The effect of 
sequence context on the reactivity of a Gly-Cys motif as monitored by 13C 
NMR at 60 oC in 10% w/v (~0.7 M) MESNa. 
was also observed in the case of N-alkylated cysteine 
derivatives.  In this case intramolecular catalysis by the carboxyl 
group is proposed since the scissile amide bond in N-alkyl Cys 
derivatives are non-planar and the amide nitrogen is 
considerably more basic.46 
 At first glance these findings could appear to impose 
significant limitations on the N→S acyl transfer reaction in that 
thioester formation may be restricted to a few favourable 
terminal Xaa-Cys motifs.  Furthermore slow reactions cannot be 
easily accelerated by increased heating or heating time, because 
this is often met with a loss of selectivity, peptide precipitation 
and thioester hydrolysis.  However the notion that simple 
peptide sequences adorned with a single C-terminal cysteine 
could undergo thioester formation with a high degree of 
inherent selectivity, and be compatible with chemically fragile 
post-translational modifications such as glycosyation44, 47, 48 and 
phosphorylation48 (Figure 2), led us to investigate further.  
 
3  Reduced reactivity of internal Xaa-Cys motifs as an 
advantage in head-to-tail peptide cyclisation.  
The difference in reactivity between identical yet differentially 
disposed (terminal vs internal) Xaa-Cys motifs additionally 
suggested that, if the thioester precursor contained an N-
terminal cysteine, this feature could drive peptide cyclisation 
reactions.  Head-to-tail peptide cyclisation to afford an “inert” 
product is an ideal application since, in forming a cyclic product, 
interference from side-reactions such as thioester hydrolysis 
are also minimised when cyclisation is rapid.45  Although acyl 
transfer reactions utilising cysteine as the acyl transfer 
facilitator are often described as sluggish, we have found that 
several short peptides cyclise completely in 6-24 h at 40-50 oC 
in aqueous buffer.45  Furthermore the reaction conditions are 
capable of facilitating effective cyclisation at Ser-Cys, Arg-Cys, 
Phe-Cys, and Leu-Cys motifs.   Although we have demonstrated 
the cyclisation reaction countless times using short (usually 
anti-microbial) peptide substrates it is still remarkable that a 
linear peptide, in all its complexity, will undergo a selective 
amide bond cleavage followed by selective peptide coupling  in 
water and in the absence of enzymes or chemical coupling 
reagents (Figure 3 ).49  We have also applied head-to-tail
                                                                                                                                                                                                                                                                
Figure 2  A selection of experiments performed on Xaa-Cys terminated peptides.  Reaction with MESNa at 40-60 oC is sufficient to convert linear precursors into  
thioesters and cyclic peptides.  For intermolecular NCL reactions the MESNa thioester is usually isolated first.  Aha =azidohomoalanine.
b) 
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Figure 3  Likely progression from linear precursor to head-to-tail cyclized 
peptide via an initial N→S acyl transfer. 
cyclisation to some short peptides (7-10 residues) that are 
usually constrained by a disulphide bond between the C and N-
termini and found, where tested, that the bioactivity of the 
peptide was maintained.  Although not examined in detail, it is 
likely that the products are also considerably more stable 
metabolically.  
 It is expected that, as the length of an unfolded peptide 
increases, the efficiency of the cyclisation reaction decreases but 
this remains an interesting challenge to address.  Successful and 
efficient cyclisation using N→S acyl transfer in one-pot is the 
outcome of a considerable balancing act, which depends on the 
ability of each player (thioester formation, cyclisation and 
hydrolysis) to perform.  Cysteine promoted thioester formation 
is favoured at lower pH yet the cyclisation is favoured at neutral 
to mildly basic pH and so the reaction conditions are usually not 
ideal for either process.  However, if the appropriate balance 
cannot be achieved then the potential remains to perform the 
cyclization in steps. Performing the reaction at lower pH allows 
isolation of the thioester intermediate and then cyclisation, 
under regular NCL conditions, can be conducted after 
purification.  In native peptide sequences the efficiency of 
cyclisation of longer peptides is most compromised by 
competing hydrolysis during prolonged heating of the 
intermediate thioester when the cyclisation step is slow. 
Nevertheless peptides up to approximately 30 amino acid 
residues have been successfully cyclised to date (see section 4). 
 
 4  Reduced reactivity of internal Xaa-Cys motifs as an 
advantage in modification and cyclisation of biologically 
produced precursors.  
It had not escaped our attention that, since cysteine is a 
naturally occurring amino acid, our method could be translated 
to biologically derived precursors and so complement intein-
mediated approaches.  While there is no shortage of available 
methods for the production of synthetic thioesters, inteins stand 
alone as the sole facilitators of N→S acyl transfer in recombinant 
proteins, yet there are countless thioesters that have proved 
recalcitrant to intein-mediated thiolysis.  This is usually because 
the precursors are unfolded and so the inactive intein fusion is 
directed into inclusion bodies, or the fusion protein possesses 
unfavourable extein sequences adjacent to the splice junction.  
Alternatively, the linkage can be too reactive and undergo 
significant hydrolysis inside the cell.  Consequently, as a very 
doable alternative, cysteine promoted N→S acyl shift should be 
a welcome addition to the protein semi-synthetic toolbox.  The 
obvious advantages of employing biologically produced 
precursors, in general, are that water can employed as the 
solvent for chain assembly as well as cyclisation, the peptide 
chain can be produced sustainably at scale using renewable 
materials, and does not require excess protected amino acids or 
coupling reagents.   
 A potential disadvantage of employing a biological 
precursor is that we cannot readily distinguish between 
cysteine residues in an expressed polypeptide.  However the 
inherent differences in reactivity between terminal and internal 
Xaa-Cys motifs towards N→S acyl shift suggested that under 
non-forcing conditions it should be possible to achieve 
selectivity in thioester formation and this was indeed found to 
be the case.50  Using Ubiquitin as an example (approximately 10 
kDa as a His-tagged fusion protein purified from E. coli) we first 
showed that “well behaved” proteins (soluble, folded, and free 
of additional cysteine residues) would undergo smooth C-
terminal thioester formation.  Thiolysis was more rapid at 60 oC 
but reactions on recombinant proteins are normally conducted 
at 50oC or below because, in earlier unpublished experiments, 
we already knew that C-terminal thioester formation needed to 
be conducted below 50 oC with Green Fluorescent Protein (GFP) 
in order to prevent loss of sample fluorescence.  We then also 
went on to show that recombinant samples containing as many 
as 6 additional cysteine residues would readily undergo 
selective N→S acyl transfer.  
 Constrained, often cysteine rich, cyclic peptides are gaining 
significant momentum as therapeutic lead structures.51  This is 
primarily due to their attractive blend of potency, selectivity and 
extraordinary chemical and metabolic stability, which is 
conferred upon them by the presence of a head-to-tail cyclic 
backbone and a network of intramolecular disulphide bonds.52 
Furthermore, regions of these peptides can be replaced with 
alternative peptide sequences without loss of structure or 
stability and this “grafting” process can be used to protect 
otherwise fragile bioactive peptides from metabolic 
degradation.  Although several chemical methods exist for their 
production, the reliance on solid-phase assembly of the linear 
precursor compromises their commercial viability.  Because 
these cysteine rich peptides are all relatively short (14-40 amino 
acid residues) the synthetic genes which are codon optimised 
for bacterial expression can be readily purchased from several 
sources at low cost and so little molecular cloning expertise is 
required.  Of the existing methods available to cyclise 
unprotected peptides inteins,32, 53 butelase54 or sortase55 appear 
the most attractive.  However inteins often fail to produce short 
cysteine rich peptides efficiently unless produced in yeast,56 
Butelase has yet to be cloned and still relies on isolation of the 
active enzyme and Sortase A generally requires that its 
recognition consensus sequence is incorporated into the cyclic 
product.  So, evaluation of new methods for the cyclisation of 
short cysteine rich linear precursors at low cost, with low 
environmental impact, could be considered a worthy pursuit.   
 To this end we over expressed common cyclic peptide 
scaffolds including prototypical cyclotide Kalata B1 (KB1) and 
sunflower trypsin inhibitor (SFTI-1) as linear precursors in E. 
coli, (Figure 4) and only four subsequent processing steps 
(protein isolation, affinity tag cleavage, cyclisation and 
oxidation) were required in order to produce SFTI-1 and 
 
NCL
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Figure 4  a) left: Purification of linear Kalata B1-Thioredoxin fusion (Trx-KB1) 
from E. coli using an Ni2+ affinity column.  M = molecular weight markers. Lane 
1 = whole cell lysate, lane 2 = soluble fraction, lane 3 = insoluble fraction, lane 
4 = column flow-through, lanes 5-6 = 5-20 mM imidazole washes, lanes 7-11 
= Eluted fractions (40-500 mM imidazole).  middle:  TEV protease digestion of 
the fusion protein shows accumulation of Trx (released linear KB1 is not 
visible on the gel). right: KB1 is isolated by preparative reverse phase HPLC.  
b) Cyclization of the isolated linear precursor and oxidative refolding in 0.1 M 
NH4HCO3 pH 8.5/iPrOH (1:1) produce correctly folded kalata B1.  
cyclotide analogues in sufficient quantities for structural 
confirmation and bioactivity assays.  Generally, each thioester 
precursor was fused to the C-terminus of polyhistidine-tagged 
thioredoxin (Trx) which facilitated stable expression and easy 
visualisation using SDS-PAGE, which would otherwise not be 
trivial owing to their small size.  A single step purification on a 
Ni2+ column followed by exposure to Tobacco Etch Virus (TEV) 
protease allowed the linear precursor to be isolated by 
preparative HPLC.  From 1 L of bacterial cell culture 60 mg 
(unoptimised) of Trx-KB1 fusion protein was obtained and after 
exposure to TEV protease the linear KB1 precursor was isolated 
in 23% yield.  Kalata B1 was finally produced following 
backbone cyclisation (45 oC for 48 h) and oxidative refolding.  
The correct cyclotide fold was confirmed by NMR analysis of the 
final product and comparison with an authentic sample.  The 
ease with which this peptide, containing 6 additional Cys 
residues, underwent cyclisation is noteworthy and may have 
benefitted from a “thia-zip” type cyclisation mechanism where 
cyclisation is aided by successive intramolecular thiolactone 
forming reactions which ultimately bring the termini into close 
proximity.57  An identical process was adopted to produce 
variants of 14 residue SFTI-1 which were ultimately tested as 
inhibitors of Kalikrein 5 (KLK5), a protease involved in skin 
barrier homeostasis.45, 58  
 Overall, rather than constituting a severe limitation, the 
differing responses of Xaa-Cys motifs toward thioloysis and the 
reduced reactivity at internal Cys residues has in fact proved 
very beneficial on several occasions.  A rather general strategy 
has been adopted for producing SFTI and cyclotide analogues 
from linear precursors and it is likely that this approach could 
be extended to other classes of cyclic peptides and combined 
with unnatural amino acids using an expanded genetic code,59 in 
order to introduce novel functionality.  Furthermore, when the 
thioester is only generated fleetingly, as in a cyclisation process, 
hydrolysis can become less problematic.  This phenomenon has 
allowed us to tackle a significant technical obstacle associated 
with cyclisation at scale.  Although linear peptide precursors can 
be generated sustainably using bacteria, the cyclisation usually 
employs MESNa at high concentrations (0.7 M) and large 
reaction volumes are laborious to purify by HPLC as they cannot 
be easily concentrated owing to the high MESNa concentration.  
However, in cyclisation reactions MESNa can often be replaced 
with 3-mercaptopropanol (3-mPrOH), a relatively poor-
performing thiol when applied to linear thioesters, owing to 
competing SO acyl shift resulting in ester products.  
Fortuitously 3-mPrOH can be employed cleanly in several 
cyclisation reactions and, in contrast to MESNa, can be easily 
extracted from the reaction mixture into ethyl acetate and 
potentially be reused.45  This advance means that reactions 
conducted at scale can be concentrated over 200-fold prior to 
purification, resulting in a streamlined process for large scale 
recombinant cyclic peptide production.  
 
5  Hydrazinolysis of Xaa-Cys motifs and the acyl hydrazide 
as a stable thioester equivalent 
In our experience to date, there are few peptides meeting the 
criteria for a favourable reaction (good aqueous solubility with 
a reactive C-terminal Xaa-Cys motif) that subsequently fail to 
furnish a thioester product.  The efficiency of the reaction, as 
evidenced by the yield of isolated product, and clarity of the 
HPLC trace, is however dependent on a number of additional 
factors.  Short peptides containing Asp-Gly sequences are 
particularly prone to aspartimide formation if reactions are 
conducted at elevated temperature (50-60 oC) for as long as 48 
h.  Poor reaction yields tend to be observed when thioester 
formation is especially slow (>48 h to reach >50% conversion), 
and usually when the peptide is especially prone to aggregation 
upon heating or has low aqueous solubility at the start.  Most 
poorly soluble peptides can be dissolved using chaotropes such 
as 6 M guanidinium hydrochloride or 6-8 M urea but, while 
peptides remain soluble in the denaturant, progress can remain 
painfully slow.  Also, urea should be avoided since peptide 
carbamylation can occur under the reaction conditions.  The 
problems are exacerbated by oxidation of the excess thiol 
additive, required for transthioesterification, over prolonged 
reaction times.  This is difficult to observe when MESNa is 
employed owing to its high polarity but the symptoms are 
clearly visible as the reaction will grind to a halt.   Progress can 
be resumed by the addition of fresh reagents, which is easy to 
do with larger proteins under non-denaturing conditions using 
a centrifugal filter with an appropriate molecular weight cut-off.  
However this is more challenging with shorter peptides and so 
we have also sought improved methods that reduce the need for 
prolonged heating at acidic pH.  
 One potential solution is to use the acyl hydrazide (4, Figure 
5 a) as a stable thioester precursor.60  An increasing number of 
researchers are employing the acyl hydrazide as a thioester 
precursor because of its stability, relative ease of synthesis and 
greater flexibility in terms of synthetic strategy and tactics.23, 61  
Once formed, 4 can be converted to a thioester via diazotisation 
and thiolysis of an acyl azide intermediate (5).  Indeed, the 
thioester need not be isolated at all and the diazotisation and 
subsequent NCL can be conducted in one pot, minimising the 
opportunity for thioester hydrolysis.  Although we have not 
studied hydrazinolysis in combination with N→S acyl transfer 
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Figure 5 a) In the presence of Hydrazine, added as hydrazinium acetate, the thioester can be intercepted and undergo quantitative hydrazinolysis with minimal 
hydrolysis.  The hydrazide (4) can be converted back to a thioester rapidly at low temperature via diazotisation. b) LC-MS analysis of a model peptide (Hepcidin 1-25) 
upon thiolysis with MESNa (left) and hydrazinolysis (right) for 48 h at 60 oC.  c) 13C NMR monitoring of hydrazinolysis (solid lines) relative to thioester formation (dashed 
lines). d) Recombinant His10-ubiquitin modified as a C-terminal hydrazide after exposure to hydrazinium acetate (40 oC, 48 h). 
extensively, a number of advantageous features were quick to 
emerge.  First, the hydrazide product is stable and does not 
hydrolyse over a prolonged reaction time.  We applied C-
terminal hydrazinolysis to peptides that failed to form 
thioesters efficiently under typical reaction conditions and 
found that the results were much improved (Figure 5b).  Second, 
the rate of hydrazinolysis is significantly faster when compared 
to thioester formation, allowing us to perform reactions at lower 
temperatures (40-50 oC).  The faster reaction may be a 
consequence of the greater nucleophilicity of hydrazine relative 
to the thiol of MESNa, but also the inability of the acyl hydrazide 
to exchange with the liberated cysteine residue once formed.  
Interestingly no reaction (other than peptide degradation) is 
observed when MESNa is absent from the reaction mixture 
suggesting that hydrazine either intercepts the MESNa thioester 
rather than the S-peptide intermediate, or MESNa performs an 
additional protective role.  Notably the final reaction pH is 
generally raised upon the addition of hydrazinium acetate to 
nearer pH 7 and C-terminal carboxylates still undergo 
hydrazinolysis faster than C- terminal carboxamides (Figure 5c).  
In summary, thioesters that were poorly accessible using typical 
reaction conditions can alternatively be formed rapidly from 
hydrazides under denaturing conditions below 0oC, so avoiding 
the conditions that can drive peptide precipitation (prolonged 
heating at acidic pH). 
   Like others, we have utilized synthetic acyl hydrazides 
(produced via N→S acyl shift) for the assembly of synthetic 
peptides using NCL, but have additionally investigated 
hydrazinolysis of biological samples.  As with biological 
thioester synthesis, the protein hydrazide (Figure 5d) is also 
accessible by intercepting intein fusions and backbone 
oxoesters with hydrazine.62 The latter can be introduced in 
response to an evolved mutant pyrrolysyl-tRNA synthetase 
(PylRS) from M. barkeri , engineered to incorporate α-hydroxy 
acid analogues of pyrrolysine in a bacterial system.63  Our 
straightforward method of hydrazide production may well 
prove attractive for C-terminal protein labelling or conjugation, 
particularly where the more common approaches fail. 
 
6  Rapid thioester formation via an N→Se acyl shift 
A banal extension to increase the reactivity of the Xaa-Cys 
system was to examine selenocysteine in place of cysteine as an 
acyl transfer facilitator, and so we were first to investigate the 
use of selenocysteine (Sec, U) for this purpose.64  The superior 
nucleophilicity and leaving group properties of selenols (in NCL) 
had already been widely reported and utilized advantageously 
through elegant prior work by Raines,65 Hondal,66 Van der 
Donk,67 and Hilvert.68  This significant precedent allowed us to 
easily assemble peptides furnished with a C-terminal Sec 
residue, the only significant challenge being removal of Se 
protecting groups (usually p-methoxybenzyl) to liberate the free 
selenol for N→Se transfer. 
 With nitropyridyl selenosulfides (6, Figure 6) in hand we  
 
Figure 6 Examining MESNa thioester formation from 6 at 40, 50 and 60 oC 
over 24 h.  Considering the use of the carboxamide terminated precursor 
these reactions are relatively fast with almost complete reaction within 
nearly 6 h at 60oC. 
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were able to show that, under reducing conditions (in the 
presence of tris-carboxyethyl phosphine (TCEP)), thioester 
formation occurred rapidly.  Reactions performed at 60 oC were 
essentially complete in less than 6 h.  Efficient thioester 
formation was also observed at 40 oC although in all reactions 
slightly more hydrolysis was observed to occur relative to the 
corresponding (Xaa-Cys) terminated peptide.  Despite the very 
promising results in model systems (short peptides devoid of 
additional Sec or Cys residues) the reaction was poor when 
applied in a more “realistic” setting.  This was likely due to the 
strong tendency for Sec to form less reactive diselenide and 
selenosulfide bonds, both of which could be observed by LC-MS 
analysis of reaction mixtures.69  The ability to balance reducing 
conditions with minimal deselenization70 was also difficult to 
achieve but recent research by the Hondal group, where selenol 
species are liberated from nitropyridyl selenosulfides through 
ascorbolysis may yet provide a way forward.71  
 Several other groups have also explored the synthesis and 
use of selenoesters in ligation processes72 73 In a notable 
example Melnyk and co-workers showed that selenocysteine 
(present within peptide sequences as Xaa-Sec) was able to 
undergo N→Se acyl transfer in the context of transamidation 
reactions,74 confirming our findings that Xaa-Sec motifs, present 
in whatever context, were significantly more reactive than the 
corresponding Xaa-Cys motif.  This research showed that Sec 
containing peptides were capable of undergoing transamidation 
at 37 oC, albeit requiring a specialised selenophosphine 
(TCEP=Se) reagent to prevent deselenization, as well as 
catalysis by MPAA.  We and others 75 others have confirmed that 
transamidation via internal or terminal Xaa-Cys motifs, outwith 
the context of intramolecular lactamization, is extremely 
inefficient at pH 7, even at elevated temperature.  We previously 
observed what was presumed to be a similar reaction of Xaa-Cys 
terminated peptides in the form of peptide concatenation (as a 
minor nuisance), when performing cyclisation reactions at 
higher concentration.   
 
7  Future outlook and conclusion 
Up to this point our research has been mainly focussed on 
examining N→S acyl transfer activity in the context of native 
peptide (Xaa-Cys) sequences, comparing their differing 
aptitudes for N→S acyl transfer as well as the relative reactivity 
of multiple “identical” Xaa-Cys motifs.  We have also attempted 
to accelerate N→S acyl transfer through evaluation of various 
alternative water soluble thiols, under a range of reaction 
conditions, and in the presence of new additives but thus far 
MESNa has produced the most stable thioesters.  Currently 
utilizing N→S acyl transfer in combination with hydrazinolysis 
shows most promise for delivering thioesters and ligation 
products from native peptides under the mildest conditions.  We 
have operated under a self-imposed limitation that our best 
process should be directly transferrable to biologically derived 
samples thus retaining the requirement for Cys (or Sec) in 
unmodified form.  The development of acyl transfer catalysts 
that have increased solubility (relative to MPAA) at lower pH 
have also been of much interest to us, particularly in the context 
of cyclisation reactions, since these reactive intermediates could 
potentially enhance such a process despite low stability of the 
corresponding linear thioester towards hydrolysis. 76  In 
countless favourable cases selective thiolysis of Xaa-Cys 
terminated peptides is sufficient to afford valuable peptide 
thioesters and cyclic peptides and, as a possible alternative we 
also investigated employing Xaa-Sec motifs.  Although using 
selenocysteine to facilitate the chemistry is attractive at first 
sight both in chemical and biological terms, the capricious 
nature of this doppelganger (in our hands at least) means that it 
is likely to remain a muse for specialists.   
 From the research undertaken in this burgeoning area over 
the past 5-10 years it is clear that several scaffolds other than 
Cys (3) can function effectively in N→S acyl shift reactions 
(Scheme 4) including the CPE (2), acyl transfer auxiliaries (7),9, 
10, 77 N-alkyl cysteine derivatives (8),75, 78 α-Methyl cysteine 
(9),75 enamide 10,79 thioethylbutylamides (TEBA, 11),80 bis-(2-
sulfanyl/selenylethyl)amides (bis-S(e)EAlide, 12),82 









Scheme 4  N→S acyl transfer promoted by a single Cys residue and some N→S acyl transfer devices that have been developed to date.19, 81 
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sulfanylethylanilides (SEAlide, 13),72, 83 selenocysteine (14),64, 
74and N-Sulfanylethyl aminooxybutyramide (SEAoxy, 15).84  The 
majority of these possess greater acyl transfer activity than 
cysteine under similar reaction conditions,19, 85 although most 
similarly require acidic pH and/or elevated temperature for 
optimal performance.   In some cases a real “witches brew” of 
additives, including a high concentration of TCEP, which is known 
to potentially damage protein samples,86 and an inert 
atmosphere are also required in order to initiate the chemistry.  
Meanwhile, we have found that in several reactions of Xaa-Cys 
terminated peptides that TCEP can be omitted or replaced with 
sodium ascorbate.87  The most widely adopted method for 
thioester synthesis via an N→S acyl shift will ultimately be a 
compromise between the most affordable/user friendly, and 
thioester yield.  Only these features will likely be competitive 
with more common and reliable approaches.18  A key 
consideration that is often overlooked is the difficulty in loading 
the first amino acid and on those grounds 9 and 15 appear 
particularly attractive since the peptide is assembled using 
typical resins, coupling reagents and protocols.  
 Despite the greater reactivity of 7-15 relative to 3 there is 
currently little scope to combine them with the benefits of 
routine biological production.  The desire to utilise biological 
precursors will not be universally shared but only once this 
conceptual and practical leap is made may the power of thioester 
synthesis through N→S acyl transfer be fully realised.   In this 
respect it may be challenging to introduce N-alkylated amino 
acids because their slow incorporation by the translation 
machinery can lead to termination of the synthesis and a 
truncated product.88  Consequently α-Methyl cysteine terminated 
peptides could be particularly attractive for this purpose.  The 
CPE (2) has already been incorporated successfully into short 
linear and cyclic peptide sequences using an engineered in vitro-
transcription-translation system.89  The encoded CPE was used to 
effect head to tail cyclisation of short peptides containing 
additional non-canonical amino acids.  To the best of our 
knowledge there are no reports of its extension to “regular” 
proteins.  Using genetically encoded cysteine analogues at the C-
terminus of proteins is likely to produce recombinant proteins 
that can be processed more reliably, with tuneable initiation of 
N→S acyl transfer in the test-tube or inside cells.  The process 
would be complementary to already extremely powerful intein-
mediated methods and provide genuine contingency for the 
countless instances where the most widely available intein-
fusions fail to produce a thioester product.  Peptides under study 
may neither need to be expressed as fusions nor be fully folded, 
and those also containing an N-terminal cysteine residue may 
cyclise spontaneously inside cells.  
 Peptides can also be cyclised via alternative modes such as 
head-to-sidechain and tail-to-sidechain to form novel branched 
topologies,90 and consequently the use of N→S acyl transfer in 
concert with unnatural amino acid mutagenesis has the potential 
to take acyl transfer reactions into this exciting new arena, 
particularly because inteins are incapable of performing N→S 
acyl transfer at the sidechain of amino acids.  Melnyk and co- 
workers have already shown how the bis-SEALide (12), when 
appended to the side chain of Asp and Glu to afford 16 (Figure 
7a) can facilitate sidechain activation in synthetic peptides, 
affording tail-to-sidechain cyclised products.91 This process 
could be highly transformative if such devices can be 
incorporated into biologically produced proteins.  The products 
of such a process should more generally enable site-selective 
carboxyl activation in recombinant proteins that can be targeted 
with nucleophilic payloads (e.g. fluorescent label, PEG, or 
carbohydrates that are available as hydrazine or aminooxy 
derivatives, or through NCL).  Fascinatingly most of the tools 
required to enable the  genetic encoding of branched dipeptides 
such as 18-20 (Figure 7b) are already available and the fact that 
dipeptide 21 and further analogues have already been encoded, 
enabling NCL at the sidechain of Lys residues,92 sets a significant 
precedent. The ability to conduct sidechain activation and 
cyclisation reactions under native-like conditions, and/or with 
the aid of reversible tethers, may ultimately bring the challenging 
peptide scaffolds such as the lariat peptide (Figure 7c) under the 
command of the synthetic chemist.93   
 In conclusion, our unanticipated diversion from glycopeptide 
synthesis took us on a new adventure in peptide thioester 
chemistry.  With further refinement our approach surely 
presents a number of opportunities for applications relevant to 
peptide and protein engineering.  N→S acyl transfer in native 
peptide sequences may not be the most effective means to 
produce thioesters but in countless examples to date it is has 
proved “good enough”, while its obvious simplicity renders it 
amenable to chemical and biological samples alike.  Furthermore, 
the ease with which biological protein production can be scaled 
could render this approach very attractive, trumping total 
chemical synthesis, for the production of various cysteine rich 
cyclic peptides, which are a rapidly growing class of therapeutics.   
 
Figure 7 a) tail-to-sidechain peptide cyclisation enabled by the bis-SEAlide 
appended to Asp or Glu. b)  Dipeptides that could potentially be genetically 
encoded to facilitate sidechain N→S acyl shift (18-20) alongside N-cysteinyl 
lysine (21) that has already been genetically encoded to enable sidechain 
ubiquitination via NCL. c) Antimicrobial lariat peptide microcin J25, a potential 
target for synthesis via sidechain N→S acyl transfer. 
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 In future the combination of biological peptide production 
with access to new topologies, and using optimised methods that 
are compatible with existing NCL streamlining practices could 
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